Clinical Trial Update: UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports a Phase 1/2 study of UTD1 in combination with Capecitabine for metastatic HER2-negative breast cancer with brain metastases, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• UTD1

Snippet

Sponsor: Hunan Cancer Hospital | Conditions: Metastatic HER2 Negative Breast Carcinoma, Brain Metastases | Phase 1, Phase 2 | Status: RECRUITING